These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
235 related items for PubMed ID: 9833534
1. [Variant type von Willebrand disease with defective binding to factor VIII]. Shima M. Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):430-3. PubMed ID: 9833534 [No Abstract] [Full Text] [Related]
2. Update on the management of von Willebrand disease. Federici AB. Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438 [No Abstract] [Full Text] [Related]
3. [Acquired von Willebranol syndrome--its pathophysiology, diagnosis and treatment]. Mohri H. Rinsho Ketsueki; 2001 Jul; 42(7):525-36. PubMed ID: 11524842 [No Abstract] [Full Text] [Related]
4. Prophylaxis in von Willebrand disease. Franchini M, Targher G, Lippi G. Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944 [Abstract] [Full Text] [Related]
6. Identification of a His54Gln substitution in von Willebrand factor from a patient with defective binding of factor VIII. Rick ME, Krizek DM. Am J Hematol; 1996 Apr; 51(4):302-6. PubMed ID: 8602631 [Abstract] [Full Text] [Related]
9. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Casonato A, Steffan A, Pontara E, Zucchetto A, Rossi C, De Marco L, Girolami A. Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996 [Abstract] [Full Text] [Related]
10. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA. Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936 [Abstract] [Full Text] [Related]
12. Diagnosis and management of von Willebrand disease in Iran. Cohan N, Karimi M. Semin Thromb Hemost; 2011 Jul; 37(5):602-6. PubMed ID: 22102206 [Abstract] [Full Text] [Related]
13. Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease. Trossaërt M, Flaujac C, Jeanpierre E, Drillaud N, Sigaud M, Fouassier M, Ternisien C, de Raucourt E. Haemophilia; 2020 Mar; 26(2):e44-e48. PubMed ID: 31865618 [No Abstract] [Full Text] [Related]
14. [Importance of the study of the binding of factor VIII to von Willebrand factor in hemophilia A]. Batlle J, Blanco-López MJ, Castiñeira MP, López-Fernández MF. Sangre (Barc); 1992 Jun; 37(3):211-24. PubMed ID: 1359656 [No Abstract] [Full Text] [Related]
15. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings. Michiels JJ, van Vliet HH, Berneman Z, Schroyens W, Gadisseur A. Acta Haematol; 2009 Jun; 121(2-3):167-76. PubMed ID: 19506363 [Abstract] [Full Text] [Related]
17. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U. Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [Abstract] [Full Text] [Related]